Basilea Pharmaceutica (BSLN) Price & Analysis

Compare

7 Followers

BSLN Stock Chart & Stats

CHF53.60

CHF0.45(0.96%)

At close: Mar 06 4:00 PM EST

CHF53.60

CHF0.45(0.96%)

Day’s Range― - ―

52-Week RangeCHF37.50 - CHF59.70

Previous CloseN/A

Volume30.09K

Average Volume (3M)41.01K

Market Cap

CHF652.87M

Enterprise ValueCHF614.24M

Total Cash (Recent Filing)CHF128.37M

Total Debt (Recent Filing)CHF96.79M

Price to Earnings (P/E)8.9

Beta1.12

Next Earnings

Feb 17, 2026

EPS Estimate

1.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.26

Shares Outstanding13,318,449

10 Day Avg. Volume32,790

30 Day Avg. Volume41,007

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)6.17

Price to Sales (P/S)2.40

P/FCF Ratio6.88

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF87.00

Price Target Upside62.31% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partnerships And CollaborationsBasilea announced a partnership with Phare Bio Inc., a biotech social venture that uses artificial intelligence to accelerate antibiotic discovery and development.

Pipeline DevelopmentBasilea's portfolio includes a potential successor to Cresemba—fosmanogepix—which could secure approval in multiple territories before Cresemba sales decline.

Product Growth And Market ExpansionThe antifungal franchise of Basilea, particularly Cresemba, is expected to continue demonstrating strong growth in the near- and medium-term.

Bears Say

Clinical Candidate SetbacksSetbacks with clinical-stage candidates, notably fosmanogepix, pose a risk to Basilea's future growth.

Global Optimization RisksRisks include the inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally.

Basilea Pharmaceutica News

Basilea Pharmaceutica Completes Key Study on Fosmanogepix in Hepatic Impairment

Basilea Pharmaceutica ($CH:BSLN) announced an update on their ongoing clinical study. In a recent clinical study update, Basilea...

5d ago

BSLN

Basilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Basilea Pharmaceutica, retaining the price target of...

7d ago

Basilea Achieves Sales Milestone with Cresemba in Europe

Basilea Pharmaceutica ( ($CH:BSLN) ) just unveiled an announcement. Basilea Pharmaceutica announced a USD 30 million sales milestone...

2M ago

Basilea Secures BARDA Funding for Novel Antibiotic Development

An announcement from Basilea Pharmaceutica ( ($CH:BSLN) ) is now available. Basilea Pharmaceutica AG announced that it has...

3M ago

Basilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright maintained a Buy rating on Basilea Pharmaceutica, boosting the price target to...

3M ago

Basilea Secures Additional BARDA Funding for Antifungal Development

An announcement from Basilea Pharmaceutica ( ($CH:BSLN) ) is now available. Basilea Pharmaceutica announced that the US Biomedical...

3M ago

Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment

Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Basilea Pharmaceutica is conducting a Phase 3...

3M ago

BSLN

Basilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges

Basilea Pharmaceutica (($CH:BSLN)) has held its Q2 earnings call. Read on for the main highlights of the call....

4M ago

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment

Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Basilea Pharmaceutica is conducting a Phase 3...

4M ago

BSLN

Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025

Basilea Pharmaceutica ( ($CH:BSLN) ) just unveiled an update. Basilea Pharmaceutica reported a significant financial performance in the...

4M ago

BSLN FAQ

What was Basilea Pharmaceutica’s price range in the past 12 months?

Basilea Pharmaceutica lowest stock price was CHF37.50 and its highest was CHF59.70 in the past 12 months.

What is Basilea Pharmaceutica’s market cap?

Basilea Pharmaceutica’s market cap is CHF652.87M.

When is Basilea Pharmaceutica’s upcoming earnings report date?

Basilea Pharmaceutica’s upcoming earnings report date is Feb 17, 2026 which is in 60 days.

How were Basilea Pharmaceutica’s earnings last quarter?

Basilea Pharmaceutica released its earnings results on Aug 19, 2025. The company reported CHF1.26 earnings per share for the quarter, missing the consensus estimate of CHF2.03 by -CHF0.77.

Is Basilea Pharmaceutica overvalued?

According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Basilea Pharmaceutica pay dividends?

Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here

What is Basilea Pharmaceutica’s EPS estimate?

Basilea Pharmaceutica’s EPS estimate is 1.73.

How many shares outstanding does Basilea Pharmaceutica have?

Basilea Pharmaceutica has 13,318,449 shares outstanding.

What happened to Basilea Pharmaceutica’s price movement after its last earnings report?

Basilea Pharmaceutica reported an EPS of CHF1.26 in its last earnings report, missing expectations of CHF2.03. Following the earnings report the stock price went down -7.561%.

Which hedge fund is a major shareholder of Basilea Pharmaceutica?

Currently, no hedge funds are holding shares in CH:BSLN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Basilea Pharmaceutica

Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland, focused on the development and commercialization of innovative therapies for infectious diseases and cancer. The company operates primarily in the pharmaceutical sector, with a strong emphasis on antibiotic treatments and oncology products. Basilea's core products include the antibiotic ceftobiprole, which is designed to treat complicated skin and skin structure infections, and various drug candidates aimed at addressing unmet medical needs in the fields of oncology and infectious diseases.

Basilea Pharmaceutica (BSLN) Earnings & Revenues

Historic Earnings Reports

BSLN Stock 12 Month Forecast

Average Price Target

CHF87.00

▲(62.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"CHF39","106":"CHF106","55.75":"CHF55.8","72.5":"CHF72.5","89.25":"CHF89.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF87.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,55.75,72.5,89.25,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.95,53.261538461538464,57.573076923076925,61.88461538461539,66.19615384615385,70.50769230769231,74.81923076923077,79.13076923076923,83.4423076923077,87.75384615384615,92.06538461538462,96.37692307692308,100.68846153846154,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.95,51.87692307692308,54.80384615384616,57.73076923076923,60.65769230769231,63.58461538461539,66.51153846153846,69.43846153846154,72.36538461538461,75.2923076923077,78.21923076923076,81.14615384615385,84.07307692307693,{"y":87,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.95,50.4923076923077,52.034615384615385,53.57692307692308,55.11923076923077,56.66153846153846,58.20384615384616,59.746153846153845,61.28846153846154,62.830769230769235,64.37307692307692,65.91538461538462,67.45769230769231,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >